JACC. Cardiovascular imaging最新文献

{"title":"Myocardial Strain Imaging","authors":"Otto A. Smiseth MD, PhD ,&nbsp;Oliver Rider BA, BMBCh, DPhil ,&nbsp;Marta Cvijic MD, PhD ,&nbsp;Ladislav Valkovič PhD ,&nbsp;Espen W. Remme MSc, PhD ,&nbsp;Jens-Uwe Voigt MD, PhD","doi":"10.1016/j.jcmg.2024.07.011","DOIUrl":"10.1016/j.jcmg.2024.07.011","url":null,"abstract":"<div><div>Myocardial strain imaging by echocardiography or cardiac magnetic resonance (CMR) is a powerful method to diagnose cardiac disease. Strain imaging provides measures of myocardial shortening, thickening, and lengthening and can be applied to any cardiac chamber. Left ventricular (LV) global longitudinal strain by speckle-tracking echocardiography is the most widely used clinical strain parameter. Several CMR-based modalities are available and are ready to be implemented clinically. Clinical applications of strain include global longitudinal strain as a more sensitive method than ejection fraction for diagnosing mild systolic dysfunction. This applies to patients suspected of having heart failure with normal LV ejection fraction, to early systolic dysfunction in valvular disease, and when monitoring myocardial function during cancer chemotherapy. Segmental LV strain maps provide diagnostic clues in specific cardiomyopathies, when evaluating LV dyssynchrony and ischemic dysfunction. Strain imaging is a promising modality to quantify right ventricular function. Left atrial strain may be used to evaluate LV diastolic function and filling pressure.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 340-381"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142251284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Echocardiographic Markers of Early Left Ventricular Dysfunction in Asymptomatic Aortic Regurgitation","authors":"Vidhu Anand MBBS ,&nbsp;Hector I. Michelena MD ,&nbsp;Christopher G. Scott MS ,&nbsp;Alexander T. Lee BS ,&nbsp;Vera H. Rigolin MD ,&nbsp;Sorin V. Pislaru MD, PhD ,&nbsp;Garvan C. Kane MD, PhD ,&nbsp;Juan A. Crestanello MD ,&nbsp;Patricia A. Pellikka MD","doi":"10.1016/j.jcmg.2024.09.005","DOIUrl":"10.1016/j.jcmg.2024.09.005","url":null,"abstract":"<div><h3>Background</h3><div>The ideal timing for surgery in asymptomatic chronic aortic regurgitation (AR) remains unclear. New thresholds for left ventricular ejection fraction (LVEF), left ventricular (LV) indexed end-systolic volume (iESV), and global longitudinal strain (GLS) have been associated with mortality in these patients. These represent markers of early LV dysfunction.</div></div><div><h3>Objectives</h3><div>The authors sought to assess the relationship between these markers (LVEF &lt;60%, iESV ≥45 mL/m², and GLS worse than −15%) and mortality, comparing them to Class I/IIa American College of Cardiology/American Heart Association guideline recommendations and absence of any of these.</div></div><div><h3>Methods</h3><div>A total of 673 asymptomatic patients with chronic clinically significant (≥ moderate-severe) AR between 2004 and 2019 at a single referral center were retrospectively analyzed. The primary study outcome was all-cause mortality.</div></div><div><h3>Results</h3><div>Mean age was 57 ± 17 years, 97 (14%) were female, 293 (45%) had hypertension, and 273 (41%) had an abnormal number of valve cusps. Aortic valve replacement was performed in 281 (48%) patients, and 69 (10%) died while under surveillance (without aortic valve replacement). LVEF &lt;60% was present in 296 (44%) patients, 122 (25%) of 482 had GLS worse than −15%, and 261 (39%) had iESV ≥45 mL/m². Mortality under surveillance was highest when Class I/IIa recommendations were present (HR: 4.22; 95% CI: 2.15-8.29), followed by the presence of 1 or more markers of early LV dysfunction (HR: 2.18; 95% CI: 1.21-3.92); no markers was used as the reference (all, <em>P</em> &lt; 0.05). LVEF showed the strongest association with mortality, statistically slightly better than GLS and iESV. In the absence of Class I/IIa recommendations, 1 marker of early LV dysfunction was associated with higher, although not statistically significant, mortality compared with no markers (<em>P</em> = 0.063), followed by 2 markers; highest mortality was when all 3 markers were present (HR: 5.46 [95% CI: 2.51-11.90]; <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Patients with asymptomatic clinically significant chronic AR incur a survival penalty when Class I/IIa guideline recommendations are attained. In patients without these recommendations, at least 2 markers of early LV dysfunction identify those with higher mortality risk who may benefit from early surgery.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 266-274"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision","authors":"Xuezhu Wang MD ,&nbsp;Kaini Shen MD ,&nbsp;Yuke Zhang BS ,&nbsp;Yajuan Gao MD ,&nbsp;Bowei Liu BS ,&nbsp;Yubo Guo BS ,&nbsp;Chao Ren MM ,&nbsp;Zhenghai Huang RA ,&nbsp;Xiao Li MD ,&nbsp;Long Chang MD ,&nbsp;Haiyan Ding PhD ,&nbsp;Hui Zhang PhD ,&nbsp;Zhuang Tian MD ,&nbsp;Marcus Hacker MD ,&nbsp;Shuyang Zhang MD ,&nbsp;Yining Wang MD ,&nbsp;Jian Li MD ,&nbsp;Xiang Li PhD ,&nbsp;Li Huo MD","doi":"10.1016/j.jcmg.2024.10.001","DOIUrl":"10.1016/j.jcmg.2024.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac involvement in amyloid light chain (AL) amyloidosis significantly influences prognosis, necessitating timely diagnosis and meticulous risk stratification.</div></div><div><h3>Objectives</h3><div>This prospective study aimed to delineate the molecular phenotypes of AL–cardiac amyloidosis (CA) by characterizing fibro-amyloid deposition using ¹⁸F-florbetapir and gallium-68-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI)-04 positron emission tomography (PET)/computed tomography (CT) imaging. The authors also proposed a novel molecular stratification methodology for prognosis.</div></div><div><h3>Methods</h3><div>Patients with confirmed AL-CA underwent echocardiography and ¹⁸F-florbetapir and ⁶⁸Ga-FAPI-04 PET/CT imaging. Cardiac amyloid burden was quantified as ¹⁸F-florbetapir cardiac amyloid volume and total cardiac amyloid. Meanwhile, cardiac fibroblast activation protein (FAP) was quantified as ⁶⁸Ga-FAPI-04 cardiac fibroblast activation protein volume (CFV) and total cardiac fibroblast activation protein (TCF). PET/CT metrics were calculated in correlation to clinical and echocardiographic markers and their association with overall survival (OS) evaluated.</div></div><div><h3>Results</h3><div>Among the 38 patients enrolled (median age: 58 years; 76.3% male), all patients exhibited amyloid deposition, and 86.8% (33 of 38) patients exhibited cardiac fibroblast activation. Cardiac amyloid burden was correlated with Mayo stage and several echocardiography metrics (<em>P &lt;</em> 0.05). In addition, there was a correlation between CFV and N-terminal pro–B-type natriuretic peptide level (<em>P &lt;</em> 0.05). Thirteen deaths occurred over a median follow-up of 24.8 months. Higher CFV and TCF were associated with shortened OS, particularly in Mayo stage III. In multivariable analysis, higher TCF was a primary determinant for shortened OS.</div></div><div><h3>Conclusions</h3><div>The study underscores that higher TCF on ⁶⁸Ga-FAPI-04 PET/CT imaging might be a correlated factor of worse clinical outcome in newly diagnosed AL-CA, and this metric seems to be a molecular imaging tool complementary to ¹⁸F-florbetapir imaging. The combination might offer a holistic understanding of molecular attributes, assisting in clinical decision-making.</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 323-336"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Diaphragm Thickness in Geriatric Patients With Heart Failure","authors":"Nobuyuki Kagiyama MD, PhD,&nbsp;Kentaro Kamiya PT, PhD,&nbsp;Misako Toki BSc,&nbsp;Hiroshi Saito PT, PhD,&nbsp;Kentaro Iwata PT, PhD,&nbsp;Yuya Matsue MD, PhD,&nbsp;Kenji Yoshioka MD,&nbsp;Kazuya Saito PT,&nbsp;Takeshi Kitai MD, PhD,&nbsp;Emi Maekawa MD, PhD","doi":"10.1016/j.jcmg.2024.09.012","DOIUrl":"10.1016/j.jcmg.2024.09.012","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 389-391"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Artery Calcium Distribution and Cardiovascular Risk","authors":"Tara Shrout Allen MD, MSc,&nbsp;Mikaila Reyes MAS,&nbsp;Jonathan M. Kermanshahchi BA,&nbsp;Julie O. Denenberg MA,&nbsp;Joseph Yeboah MD,&nbsp;Matthew A. Allison MD, MPH,&nbsp;Michael H. Criqui MD, MPH,&nbsp;Harpreet S. Bhatia MD, MAS","doi":"10.1016/j.jcmg.2024.10.005","DOIUrl":"10.1016/j.jcmg.2024.10.005","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 392-394"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Calcium in the Last Decade","authors":"Ron Blankstein MD (Associate Editor, JACC: Cardiovascular Imaging),&nbsp;Leslee J. Shaw PhD (Deputy Editor, JACC: Cardiovascular Imaging),&nbsp;Y. Chandrashekhar MD, DM (Editor-in-Chief, JACC: Cardiovascular Imaging)","doi":"10.1016/j.jcmg.2025.02.001","DOIUrl":"10.1016/j.jcmg.2025.02.001","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 399-401"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143534085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM","authors":"Milind Y. Desai MD, MBA ,&nbsp;Yuichiro Okushi MD ,&nbsp;Kathy Wolski MPH ,&nbsp;Jeffrey B. Geske MD ,&nbsp;Anjali Owens MD ,&nbsp;Sara Saberi MD, MS ,&nbsp;Andrew Wang MD ,&nbsp;Paul C. Cremer MD, MS ,&nbsp;Mark Sherrid MD ,&nbsp;Neal K. Lakdawala MD ,&nbsp;Albree Tower-Rader MD ,&nbsp;David Fermin MD ,&nbsp;Srihari S. Naidu MD ,&nbsp;Kathy L. Lampl MD ,&nbsp;Amy J. Sehnert MD ,&nbsp;Steven E. Nissen MD ,&nbsp;Zoran B. Popovic MD, PhD","doi":"10.1016/j.jcmg.2024.08.005","DOIUrl":"10.1016/j.jcmg.2024.08.005","url":null,"abstract":"<div><h3>Background</h3><div>In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), the VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) trial showed that mavacamten reduced the eligibility for septal reduction therapy with sustained improvement in left ventricular outflow tract gradients. Mavacamten also resulted in favorable cardiac remodeling, including improvement in biomarkers (eg, N-terminal pro–B-type natriuretic peptide and troponin T). However, the impact of mavacamten on left atrial (LA) function is unknown.</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess serial changes in LA strain measures in patients enrolled in the VALOR-HCM trial.</div></div><div><h3>Methods</h3><div>VALOR-HCM included 112 symptomatic patients with obstructive HCM (mean age 60 years; 51% male). Patients assigned to receive mavacamten at baseline (n = 56) continued therapy for 56 weeks and those assigned to placebo transitioned to mavacamten (n = 52) from week 16 to week 56. Echocardiographic LA strain (reservoir, conduit, and contraction) was measured by using a vendor-neutral postprocessing software.</div></div><div><h3>Results</h3><div>At baseline, the mean LA volume index (LAVI) and LA strain values (conduit, contraction, and reservoir) were 41.3 ± 16.5 mL/m², −11.8% ± 6.5%, −8.7% ± 5.0%, and 20.5% ± 8.7%, respectively (all worse than reported normal). LAVI significantly improved by −5.6 ± 9.7 mL/m² from baseline to week 56 (<em>P &lt;</em> 0.001). There was a significant (<em>P &lt;</em> 0.05) improvement in absolute LA strain values from baseline to week 56 (conduit [−1.7% ± 6%], contraction [−1.2% ± 4.5%], and reservoir [2.8% ± 7.7%]). Patients originally receiving placebo had no differences in LA measurements up to week 16. There was no significant improvement in LA strain values (conduit [−0.9% ± 3.8%], contraction [−0.4% ± 3.4%], and reservoir [1.4% ± 6.1%]; all; <em>P =</em> not significant) from baseline to week 56 in patients with history of atrial fibrillation.</div></div><div><h3>Conclusions</h3><div>In VALOR-HCM, mavacamten resulted in an improvement in LAVI and LA strain at week 56, suggesting sustained favorable LA remodeling and improved function, except in the atrial fibrillation subgroup. Whether the advantageous LA remodeling associated with long-term treatment with mavacamten results in a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM remains to be proven. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; <span><span>NCT04349072</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 251-262"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraprocedural Guidance for Transcatheter Tricuspid Valve Replacement in Challenging Scenarios","authors":"Lucy M. Safi DO ,&nbsp;Stamatios Lerakis MD, PhD ,&nbsp;Gilbert H.L. Tang MD, MSc, MBA ,&nbsp;Annapoorna S. Kini MD ,&nbsp;Parasuram Krishnamoorthy MD ,&nbsp;Samin K. Sharma MD ,&nbsp;Sahil Khera MD, MPH","doi":"10.1016/j.jcmg.2025.01.002","DOIUrl":"10.1016/j.jcmg.2025.01.002","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 382-388"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Prognostication With PET Imaging","authors":"Giuseppe Vergaro MD, PhD,&nbsp;Alberto Aimo MD, PhD,&nbsp;Dario Genovesi MD,&nbsp;Assuero Giorgetti MD,&nbsp;Michele Emdin MD, PhD","doi":"10.1016/j.jcmg.2024.11.007","DOIUrl":"10.1016/j.jcmg.2024.11.007","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Page 395"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcium Scoring and Plaque Density","authors":"Harpreet S. Bhatia MD, MAS","doi":"10.1016/j.jcmg.2024.09.004","DOIUrl":"10.1016/j.jcmg.2024.09.004","url":null,"abstract":"","PeriodicalId":14767,"journal":{"name":"JACC. Cardiovascular imaging","volume":"18 3","pages":"Pages 305-307"},"PeriodicalIF":12.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}